News
Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017
September 11, 2017
NEW YORK, Sept. 11, 2017 (GLOBE NEWSWIRE)
Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced the presentation of clinical data from the ongoing SL-801 Phase 1 trial in patients with advanced solid tumors. The data were presented at the European Society of Medical Oncology (ESMO) Annual Congress 2017 in Madrid, Spain.
Events: Featured & Upcoming
Nothing found.
Archived Events
Nothing found.